about
siRNA Delivery from an Injectable Scaffold for Wound TherapyTechnologies for controlled, local delivery of siRNATuning PEGylation of mixed micelles to overcome intracellular and systemic siRNA delivery barriers.Generation and comparison of CRISPR-Cas9 and Cre-mediated genetically engineered mouse models of sarcoma.Hydrolytic charge-reversal of PEGylated polyplexes enhances intracellular un-packaging and activity of siRNAEnhanced Performance of Plasmid DNA Polyplexes Stabilized by a Combination of Core Hydrophobicity and Surface PEGylationROS-responsive microspheres for on demand antioxidant therapy in a model of diabetic peripheral arterial disease.MiRNA inhibition in tissue engineering and regenerative medicine.In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy.Balancing cationic and hydrophobic content of PEGylated siRNA polyplexes enhances endosome escape, stability, blood circulation time, and bioactivity in vivoTunable delivery of siRNA from a biodegradable scaffold to promote angiogenesis in vivo.Engineering Delivery Vehicles for Genome Editing.Genome engineering: a new approach to gene therapy for neuromuscular disorders.Matrix Metalloproteinase Responsive, Proximity-activated Polymeric Nanoparticles for siRNA Delivery.Local Delivery of PHD2 siRNA from ROS-Degradable Scaffolds to Promote Diabetic Wound HealingDual MMP7-proximity-activated and folate receptor-targeted nanoparticles for siRNA delivery.Cas9 loosens its grip on off-target sites.RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors.Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy
P50
Q27026234-F95E742E-267F-48AF-AEF9-4A43EB74B59AQ28087657-4747649F-B6D0-4FA5-89BC-9AADE89B2202Q33816969-63146087-D7C0-4ED4-B65C-4B843EBBF4A7Q33899910-ED13363A-66A8-4030-BC8B-BC6AA34390DFQ33918054-BFC7B0AE-C067-4621-A454-220A83C25408Q34722741-71F2DC1E-C472-4359-9AD0-94D3EEA260F2Q34762292-B85CA34D-56AF-48BC-A4F8-EFE42C4A1035Q35799937-DF9946AE-0694-4527-9C25-543ABB6E8FFDQ36943717-C935D35F-4471-47DC-A050-FBC743303BB1Q37378292-3DE908EA-8269-41CC-8266-8FE789F03845Q37633993-B0814B87-C0D9-4173-B540-32915F50D8F7Q38825942-850C5BA0-8EE3-49B0-A007-6A7528F910A8Q41928233-F1F899E3-1614-44B1-9D37-CFF8021E3BF3Q42077942-24725D6C-44F8-4FF8-81C8-B1FDE41FE990Q42856140-345F1A89-88AA-44C5-BF0F-B072243F3A37Q43105872-BEDBD372-213E-427F-96F9-CE7FC30AEB57Q51454074-3D338704-710A-4BA9-9B93-EBEE9EDBF76CQ52431912-246CCFFC-947E-4774-9B96-90C6DEE8E969Q91692021-520CE699-D48F-458A-A7AA-ED0FF0358E5B
P50
description
investigador
@es
researcher
@en
name
Christopher E Nelson
@en
type
label
Christopher E Nelson
@en
prefLabel
Christopher E Nelson
@en
P31
P496
0000-0002-8423-8854